CD38 and Miyoshi myopathy: Several mAbs are currently approved for the treatment of MM: elotuzumab, an IgG1κ mAb with a specificity against SLAMF7, daratumumab and isatuximab, humanizeds IgG1 mAb that targets CD38 [125,126].